疾病中的纤维分析系统:从分子途径到临床结果
Mohamed Nazem Alibrahim1, Khaled A Sahli2, Fahad S Alshehri3
1Department of Internal Medicine, Faculty of Medicine, Zagazig University, Egypt.
Thrombosis research
|October 18, 2025
概括
纤维溶解系统可以调节血栓的形成. 它在肝病,心血管疾病,败血症和创伤中的失调影响出血和凝血,需要针对性干预以获得更好的患者结果.
科学领域:
- 生物化学 生化学
- 身体生理学 身体生理学
- 病理学 病理学 病理学
背景情况:
- 纤维溶解系统对于静血平衡至关重要,通过激活剂,抑制剂和调节剂控制血液凝块的分解.
- 纤维素分解的失调与许多病理状况有关,影响患者的健康和治疗策略.
研究的目的:
- 审查对不同临床条件中的纤维素分析机制的关键见解.
- 倡导进一步研究细化诊断和个性化干预,以调节纤维溶解系统.
主要方法:
- 本综述综合了当前关于肝病,心血管疾病,败血症和创伤中的纤维素分解的知识.
- 它分析了t-PA,PAI-1和TAFI等关键纤维解蛋白在疾病发病过程中的作用.
主要成果:
- 肝脏疾病表现出改变的纤维解蛋白 (例如,t-PA升高,PAI-1降低),导致变化的出血或血栓形成风险.
- 心血管疾病与纤维解质受损和PAI-1升高有关,增加了心脏病发作和中风的风险.
- 败血症通常会导致纤维溶解性关闭 (高PAI-1,TAFI),恶化微血栓和器官功能障碍.
- 创伤呈现出高纤维素分解 (高t-PA) 或关闭,需要不同的治疗,如tranexamic acid.
结论:
- 了解各种疾病中的纤维解质失调是临床管理的关键.
- 针对性调节纤维溶解系统为改善诊断和个性化治疗提供了潜力.
相关概念视频
Clot Retraction and Fibrinolysis
8.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis
12.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.0K
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
351
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
351
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K


